
Alexis Garcia, PharmD, senior director of business development at Tabula Rasa HealthCare, outlines how cytochrome P450 enzymes can impact medication efficacy in patients taking multiple drugs.

Alexis Garcia, PharmD, senior director of business development at Tabula Rasa HealthCare, outlines how cytochrome P450 enzymes can impact medication efficacy in patients taking multiple drugs.

Bernice Kwong, MD, clinical professor of dermatology, Stanford University, explains what dermatological considerations should be made for patients with leukemia and lymphoma.

Nathan H. Walcker, MBA, chief executive officer, Florida Cancer Specialists & Research Institute (FCSRI), discusses what guests can expect at the in-person Tampa meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), co-hosted by FCSRI.

Michael Diaz, MD, president and managing physician, Florida Cancer Specialists & Research Institute, previews the Tampa meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), cohosted by Florida Cancer Specialists & Research Institute.

Chronic kidney disease is the fastest-growing noncontagious disease in the United States. On this episode of Managed Care Cast, we speak with Mike Spigler, vice president of patient support and education for the American Kidney Fund, who is spearheading the Unknown Causes of Kidney Disease Project, which aims to help underserved patients get to the root cause of their kidney disease, while also helping to solve this mystery for a broader patient population.

Hilary Baldwin, MD, medical director, Acne Treatment and Research Center, explains the microencapsulation technology in Twyneo cream and what research went into its development.

When clinicians consider the patient journey from beginning to end, they begin to understand how difficult it is for patients to access care, said Elaine Goodman, MD, MBA, clinical lead for population health management, Mass General Brigham.

Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon, discusses the potential of certain drug classes for lung cancer.

Gary Owens, MD, president of Gary Owens Associates, outlines the current epidemiological knowledge of pulmonary arterial hypertension (PAH).

The financial toxicity of newer metastatic breast cancer (MBC) treatments is a significant concern and requires stakeholders to work together to find the best value- and evidence-based treatments for patients, said Hatem Soliman, MD, medical director, Clinical Trials Office, Moffitt Cancer Center.

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses how the pandemic may have influenced cancer screening and diagnosis rates.

Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives insight into how his practice will handle the influx of at least 7 adalimumab biosimilars referencing Humira that are expected to enter the market in 2023.

Michael Ciarametaro, MBA, vice president of research at the National Pharmaceutical Council, highlights steps clinics can take to mitigate issues related to data collection regarding cell and gene therapies.

Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, discussed findings of 2 phase 4 real-world studies on tildrakizumab, which showed that patients achieved significant improvement in severity and quality of life by week 4 of treatment.

Gary Owens, MD, president of Gary Owens Associates, outlines the challenges of screening for pulmonary arterial hypertension (PAH).

A combination of biology, access issues, and delayed diagnoses have contributed to disparities experienced by Black women with metastatic breast cancer, explained Hatem Soliman, MD, medical director of the Clinical Trials Office, Moffitt Cancer Center.

Bill Vandivier, DO, a consultant at Insight Health Partners, explains how the health care industry differs from traditional corporations with regard to consolidation.

Dexter Shurney, MD, MBA, MPH, chief health equity, diversity, and inclusion officer and chief medical officer at Adventist Health, explains the roles of health care systems and managed care organizations, and next steps to update policies, to ensure healthy food is available in all areas of the United States.

Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, discusses several pediatric patient populations with atopic dermatitis who are candidates for the use of systemic therapies.

Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, addresses the challenges of treating chronic cough.

April is Parkinson’s Disease Awareness month, and on this episode of Managed Care Cast, we take a look at the Parkinson's Progression Markers Initiative (PPMI), a study from the Michael J. Fox Foundation for Parkinson's Research (MJFF). The multicenter, international study aims to end Parkinson disease, which is expected to double worldwide by 2040, to more than 14 million people.

Marc-Andre Cornier, MD, professor and director of the Division of Endocrinology, Diabetes and Metabolic Diseases at the Medical University of South Carolina, discusses factors that could worsen US obesity rates.

Dexter Shurney, MD, MBA, MPH, chief health equity, diversity, and inclusion officer and chief medical officer at Adventist Health, discusses the concept of "food as medicine," which he will be explaining further at the National Association of Managed Care Physicians (NAMCP) Spring Managed Care Forum.

Patients may have unrealistic expectations of how a new treatment or procedure may help them, and the conversation between the patient and physician is crucial for setting expectations, explained Robert G. Fante, MD, FACS, president of the American Society of Ophthalmic Plastic & Reconstructive Surgery and facial plastic surgeon and cosmetic surgeon, Fante Eye & Face Centre in Denver, Colorado.

Stephen M. Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, previews the Nashville meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), co-hosted by Tennessee Oncology.

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses considerations for getting a second COVID-19 booster, or a fourth dose, among survivors of breast cancer or patients currently undergoing treatment as well as those who may be immunocompromised.

Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, spoke on the design of the 2 phase 4 real-world studies investigating severity and quality of life impact of tildrakizumab for the treatment of psoriasis.

To mark Black Maternal Health Week, The American Journal of Managed Care® sat down with Breana Lipscomb, the senior advisor of Maternal Health & Rights at the Center for Reproductive rights, to better understand how the United States came to have such poor maternal care, and what can be done to address disparities.

Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains current knowledge on the pathology of atopic dermatitis and use of targeted biologic therapies.

In Medicaid, delivering care needs to address the lack of resources and other socioeconomic factors that impact patients, said Steve Evans, MD, chief medical officer of SilverSummit at Centene.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
